TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at HC Wainwright

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 396.69% from the company’s current price.

A number of other research analysts have also issued reports on TCRX. Wedbush restated an “outperform” rating and issued a $7.00 target price (down from $10.00) on shares of TScan Therapeutics in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, November 12th.

TScan Therapeutics Stock Down 1.9 %

Shares of TCRX opened at $3.02 on Wednesday. TScan Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The business’s 50 day simple moving average is $4.87 and its 200-day simple moving average is $5.91. The stock has a market capitalization of $161.18 million, a price-to-earnings ratio of -2.85 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, equities analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Transactions at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the transaction, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. This represents a 12.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.76% of the stock is owned by company insiders.

Institutional Trading of TScan Therapeutics

Several hedge funds have recently made changes to their positions in TCRX. Great Point Partners LLC bought a new stake in TScan Therapeutics in the second quarter worth $5,504,000. Checkpoint Capital L.P. purchased a new stake in TScan Therapeutics during the third quarter valued at $4,110,000. State Street Corp boosted its stake in shares of TScan Therapeutics by 24.4% during the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after purchasing an additional 148,414 shares during the period. Bank of Montreal Can purchased a new position in shares of TScan Therapeutics during the second quarter worth approximately $749,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of TScan Therapeutics during the 2nd quarter worth $682,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.